Gravity Analytica

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

EXEL 11.07.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-12

Name of Upcoming Event:Guggenheim’s Inaugural Healthcare Innovation Conference

Date of Upcoming Event:2024-11-18

Name of Upcoming Event:Stifel 2024 Healthcare Conference

Date of Upcoming Event:2024-11-19

Name of Upcoming Event:Jefferies London Healthcare Conference

Full Press Release SEC Filings Our EXEL Tweets

About Gravity Analytica

Recent Filings

- Presentations to be webcast onwww.exelixis.com-

ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 7, 2024--Exelixis, Inc.(Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:

Guggenheim’sInaugural Healthcare Innovation Conference:Exelixisis scheduled to present at9:00 a.m. ET/6:00 a.m. PTonTuesday, November 12inBoston.
Stifel 2024 Healthcare Conference:Exelixisis scheduled to present at10:20 a.m. ET/7:20 a.m. PTonMonday, November 18inNew York City.
Jefferies London Healthcare Conference:Exelixisis scheduled to present at10:30 a.m. BST/5:30 a.m. ET/2:30 a.m. PTonTuesday, November 19inLondon, UK.

To access the webcast links, log ontowww.exelixis.comand proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

AboutExelixis

Exelixisis a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib).Exelixisis driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visitwww.exelixis.com, follow@ExelixisIncon X (Twitter), likeExelixis, Inc.on Facebook and followExelixison LinkedIn.

Exelixis, theExelixislogo and CABOMETYX are registeredU.S.trademarks.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241107742591/en/

Investors Contact:Varant ShirvanianDirector, Investor RelationsExelixis, Inc.650-837-7917vshirvanian@exelixis.com

Media Contact:Hal MackinsForExelixis, Inc.415-994-0040hal@torchcommunications.com

Source:Exelixis, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com